193 related articles for article (PubMed ID: 27806091)
1. Immunodominant IgM and IgG Epitopes Recognized by Antibodies Induced in Enterovirus A71-Associated Hand, Foot and Mouth Disease Patients.
Aw-Yong KL; Sam IC; Koh MT; Chan YF
PLoS One; 2016; 11(11):e0165659. PubMed ID: 27806091
[TBL] [Abstract][Full Text] [Related]
2. Antibody signatures in hospitalized hand, foot and mouth disease patients with acute enterovirus A71 infection.
You L; Chen J; Cheng Y; Li Y; Chen YQ; Ying T; Turtle L; Yu H
PLoS Pathog; 2023 Jun; 19(6):e1011420. PubMed ID: 37262073
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity Analysis of the Nonstructural Proteins of Human Enterovirus 71.
Chen X; Qin B; Shi M; Zhu L; Sun M; Liu X; Zhang J
Viral Immunol; 2017 Mar; 30(2):106-110. PubMed ID: 27870604
[TBL] [Abstract][Full Text] [Related]
4. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
[TBL] [Abstract][Full Text] [Related]
5. Screening and Identification of Linear B Cell Epitopes Within the Nonstructural Proteins of Enterovirus 71.
Zhang J; Huang H; Xu L; Lou C; Pan M
Viral Immunol; 2019 Mar; 32(2):84-88. PubMed ID: 30523737
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease.
Maje Bello A; Chaimongkolnukul K; Poomputsa K; Mekvichitsaeng P; Maprang Roshorm Y
Vaccine; 2024 Jun; 42(17):3733-3743. PubMed ID: 38705805
[TBL] [Abstract][Full Text] [Related]
7. Immune responses against enterovirus A71 infection: Implications for vaccine success.
Aw-Yong KL; NikNadia NMN; Tan CW; Sam IC; Chan YF
Rev Med Virol; 2019 Sep; 29(5):e2073. PubMed ID: 31369184
[TBL] [Abstract][Full Text] [Related]
8. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice.
Zhao H; Li HY; Han JF; Deng YQ; Zhu SY; Li XF; Yang HQ; Li YX; Zhang Y; Qin ED; Chen R; Qin CF
Sci Rep; 2015 Jan; 5():7878. PubMed ID: 25597595
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide linear B-cell epitopes of enterovirus 71 in a hand, foot and mouth disease (HFMD) population.
Zhang H; Song Z; Yu H; Zhang X; Xu S; Li Z; Li J; Xu H; Yuan Z; Ma H; Yi Z; Hu Y
J Clin Virol; 2018 Aug; 105():41-48. PubMed ID: 29886372
[TBL] [Abstract][Full Text] [Related]
10. Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease.
Fang CY; Liu CC
Expert Rev Vaccines; 2018 Sep; 17(9):819-831. PubMed ID: 30095317
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of neutralization epitopes at VP2 and VP1 of enterovirus A71.
NikNadia N; Tan CW; Ong KC; Sam IC; Chan YF
J Med Virol; 2018 Jun; 90(6):1164-1167. PubMed ID: 29457642
[TBL] [Abstract][Full Text] [Related]
12. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
[TBL] [Abstract][Full Text] [Related]
13. Identification of specific antigenic epitope at N-terminal segment of enterovirus 71 (EV-71) VP1 protein and characterization of its use in recombinant form for early diagnosis of EV-71 infection.
Zhang J; Jiang B; Xu M; Dai X; Purdy MA; Meng J
Virus Res; 2014 Aug; 189():248-53. PubMed ID: 24952304
[TBL] [Abstract][Full Text] [Related]
14. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.
Jiang H; Zhang Z; Rao Q; Wang X; Wang M; Du T; Tang J; Long S; Zhang J; Luo J; Pan Y; Chen J; Ma J; Liu X; Fan M; Zhang T; Sun Q
Emerg Microbes Infect; 2021 Dec; 10(1):619-628. PubMed ID: 33682641
[TBL] [Abstract][Full Text] [Related]
15. A Polysaccharide Purified From
Lin YL; Shih C; Cheng PY; Chin CL; Liou AT; Lee PY; Chiang BL
Front Immunol; 2020; 11():561758. PubMed ID: 33117346
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: A longitudinal cohort study in Zhengzhou during 2017-2019.
Qiu Q; Zhou J; Cheng Y; Zhou Y; Liang L; Cui P; Xue Y; Wang L; Wang K; Wang H; Li P; Chen J; Li Y; Turtle L; Yu H
EBioMedicine; 2021 Jun; 68():103398. PubMed ID: 34049245
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity of SP81 peptide against Enterovirus A71 (EV-A71).
Abd-Aziz N; Lee MF; Ong SK; Poh CL
Virology; 2024 Jan; 589():109941. PubMed ID: 37984152
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates.
Lim PY; Hickey AC; Jamiluddin MF; Hamid S; Kramer J; Santos R; Bossart KN; Cardosa MJ
Vaccine; 2015 Nov; 33(44):6017-24. PubMed ID: 26271825
[TBL] [Abstract][Full Text] [Related]
19. Is a multivalent hand, foot, and mouth disease vaccine feasible?
Klein M; Chong P
Hum Vaccin Immunother; 2015; 11(11):2688-704. PubMed ID: 26009802
[TBL] [Abstract][Full Text] [Related]
20. Genomic Epidemiology and Phylodynamic Analysis of Enterovirus A71 Reveal Its Transmission Dynamics in Asia.
Xiao J; Huang K; Lu H; Song Y; Han Z; Zhang M; Li J; Zhou X; Chen J; Yu Q; Yang M; Yan D; Ji T; Yang Q; Zhu S; Xu W; Zhang Y
Microbiol Spectr; 2022 Oct; 10(5):e0195822. PubMed ID: 36200890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
